Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Admission Serum Soluble Receptor for Advanced Glycation End Products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 as Independent Predictors of Acute Respiratory Distress Syndrome and In-Hospital Mortality Following Severe Isolated Chest Trauma: A Prospective Cohort Study.

NCT07774338 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT07774338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Admission Serum Soluble Receptor for Advanced Glycation End Products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 as Independent Predictors of Acute Respiratory Distress Syndrome and In-Hospital Mortality Following Severe Isolated Chest Trauma: A Prospective Cohort Study.
Lead sponsor
Assiut University
Phase
Observational
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2028
Enrollment
85 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, chest trauma